CAR T-cell therapy for ANCA vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with a type of ANCA vasculitis called GPA or MPA.
- Your vasculitis is active now (within the last 6 weeks) and has either come back or not gotten better after standard treatments like rituximab or cyclophosphamide.
- You have had a positive antibody test (PR3 or MPO) for vasculitis in the past, even if it's negative now.
- Your heart, liver, and kidney function must be adequate (for example, a heart pump strength above 45% and kidney filtration above 30).
- You must agree to use effective birth control (if applicable) starting before the treatment and for 12 months after.
- You cannot have had a prior CAR T-cell therapy, certain heart conditions, active infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called anti-CD19 CAR-T cells for people with active ANCA vasculitis that hasn't gotten better with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Hear when a new Antineutrophil Cytoplasmic Antibody-associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.